Clinical Trials Logo

Rhinitis, Allergic, Perennial clinical trials

View clinical trials related to Rhinitis, Allergic, Perennial.

Filter by:

NCT ID: NCT01018862 Completed - Clinical trials for Perennial Allergic Rhinitis

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of an Investigational use of an allergy medication (MP03-33) used to treat perennial allergic rhinitis (PAR) to placebo (a nasal spray that contains no medicine). In addition, the study will also compare the safety and effectiveness of an investigational use of another allergy medication (MP03-36) used to treat perennial allergic rhinitis to placebo.

NCT ID: NCT01001130 Completed - Clinical trials for Rhinitis, Allergic, Perennial and Seasonal

Regulatory AVAMYS Nasal Spray PMS

Start date: May 2010
Phase: N/A
Study type: Observational

Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of AVAMYS nasal spray administered in Korean patients according to the prescribing information. AVAMYS is a registered trademark of the GSK group of companies.

NCT ID: NCT00988247 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

Start date: October 31, 2009
Phase: Phase 3
Study type: Interventional

Subjects with perennial allergic rhinitis will be randomized to 320 mcg of beclomethasone dipropionate (BDP) using a hydrofluoroalkane (HFA) propellant or placebo as a nasal aerosol. The subjects will be followed for safety and efficacy for a period of 30 or 52 weeks. BDP HFA is a steroid which is currently FDA approved for the treatment of asthma. BDP-HFA should be safe and effective as a "dry" nasal aerosol which may be preferred by some patients.

NCT ID: NCT00974571 Completed - Clinical trials for Perennial Allergic Rhinitis

Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)

Start date: November 2001
Phase: Phase 3
Study type: Interventional

This study will assess the ability of montelukast to improve the signs and symptoms of perennial allergic rhinitis compared to placebo. Cetirizine is included in the study as an active control.

NCT ID: NCT00963573 Completed - Rhinitis Clinical Trials

Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)

Start date: September 2003
Phase: Phase 4
Study type: Interventional

This study attempts to document the therapeutic value of combining loratadine antihistamine action (no sedative) with anti-inflammatory effects of betamethasone at low doses, which may facilitate treatment adherence by patients whereas providing an effective and rapid perennial allergic rhinitis (PAR) symptoms relief.

NCT ID: NCT00953147 Completed - Allergic Rhinitis Clinical Trials

A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Start date: August 2009
Phase: Phase 3
Study type: Interventional

This is a 6-month multi-center, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide HFA nasal aerosol administered once-daily to male and female subjects 12 years or older diagnosed with perennial allergic rhinitis (PAR).

NCT ID: NCT00894231 Completed - Clinical trials for Perennial Allergic Rhinitis

Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis

Start date: January 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to noninvasively measure the anti-inflammatory effect of levocetirizine after two weeks of treatment in allergic rhinitis subjects.

NCT ID: NCT00848965 Completed - Allergic Rhinitis Clinical Trials

A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber

Start date: October 2007
Phase: Phase 4
Study type: Interventional

This is a single-centre, randomised, double-blind, four-period, incomplete block, crossover study, with 8 days repeat dosing of intranasal Fluticasone Propionate (25, 50, 100, 200ug) and/or placebo in the Vienna Challenge Chamber in subjects with allergic rhinitis.

NCT ID: NCT00839189 Completed - Asthma Clinical Trials

Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults

Start date: October 2002
Phase: Phase 1
Study type: Interventional

The purposes of this pilot safety study are to identify a dose of inhaled Clinical Center Reference Endotoxin (CCRE) that is well tolerated by allergic subjects that induces measurable increases in neutrophil content of induced sputum that can be employed to screen large populations for susceptibility to the inflammatory effect of inhaled endotoxin.

NCT ID: NCT00829985 Completed - Asthma Clinical Trials

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

Start date: January 2009
Phase: Phase 1/Phase 2
Study type: Interventional

There is currently no effective way to prevent development of allergic rhinitis (nasal allergies) and asthma and no cure. Sublingual immunotherapy (SLIT), a type of therapy in which allergens are placed under the tongue, may be a way to control and possibly prevent allergic rhinitis and asthma. However, detailed research of this approach is limited. The purpose of this study is to evaluate the safety and efficacy of a sublingual cockroach extract given to adults with perennial allergic rhinitis, asthma, or both.